Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 3,055 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Colon Clear all
Completed Phase 2 Interventional Results available

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

NCT01298570
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
Regorafenib (BAY 73-4506), FOLFIRI, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
23
States / cities
Denver, Colorado • Miami, Florida • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 29, 2026, 5:26 PM EDT
Terminated Not applicable Interventional Results available

Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)

NCT01881932
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer
Interventions
Acupuncture using Seirin® needles, Sham Acupuncture using Park Sham placebo acupuncture device
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 29, 2026, 5:26 PM EDT
Recruiting Phase 3 Interventional

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
26
States / cities
Chandler, Arizona • Fullerton, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 29, 2026, 5:26 PM EDT
Recruiting Phase 1Phase 2 Interventional

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

NCT06298916
View directory record Official record
Conditions
Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma
Interventions
64Cu-LNTH-1363S
Combination Product
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
15 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Duarte, California • Orange, California • Stanford, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 29, 2026, 5:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep

NCT01695863
View directory record Official record
Conditions
Colorectal Cancer
Interventions
comparing 2 drugs on their effect on the bowel preparation for colonoscopy
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 29, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

NCT03890731
View directory record Official record
Conditions
Solid Cancer
Interventions
BAY73-4506 (Regorafenib, Stivarga)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 29, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Phase II Trial of LBH589 in Refractory Colorectal Cancer

NCT00690677
View directory record Official record
Conditions
Colorectal Cancer
Interventions
LBH589
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Oct 29, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

NCT00004065
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tanespimycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 29, 2026, 5:26 PM EDT
Not yet recruiting Not applicable Interventional

Medically Tailored Meals to Reduce Ultra-processed Food Intake in Colorectal Cancer Survivors

NCT07701707
View directory record Official record
Conditions
Colorectal Cancer (Diagnosis)
Interventions
MTM: Medically tailored meals, MTM plus Fresh Produce, Control group
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 29, 2026, 5:26 PM EDT
Terminated Phase 2 Interventional

Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer

NCT00062023
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Acetylsalicylic acid (Aspirin), Sulindac, Ursodiol, Sulindac Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 29, 2026, 5:26 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.

NCT04739696
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Colon Cancer, Solid Tumor, Adult
Interventions
PEPRR, Pep-Pal
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 29, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

EndoRings Colonoscopy vs Standard Colonoscopy

NCT03418662
View directory record Official record
Conditions
Colorectal Adenoma, Colorectal Polyp, Colon Cancer
Interventions
EndoRings device
Device
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
592 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 29, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen

NCT00615056
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Bevacizumab (avastin), FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]), AG-013736 (axitinib), FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
61
States / cities
Mobile, Alabama • Antioch, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 29, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

NCT01006369
View directory record Official record
Conditions
Colorectal Cancer
Interventions
hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
4
States / cities
Camden, New Jersey • Hamilton, New Jersey • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 29, 2026, 5:26 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases

NCT01505166
View directory record Official record
Conditions
Colon Cancer
Interventions
Vigil™ Vaccine, Placebo
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 29, 2026, 5:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biological, Genetic, and Lifestyle Risk Factors for Developing Colorectal Adenomas or Polyps in Participants Undergoing Colonoscopy

NCT00625066
View directory record Official record
Conditions
Colorectal Cancer, Precancerous Condition
Interventions
biologic sample preservation procedure, cytology specimen collection procedure, medical chart review, questionnaire administration, survey administration, biopsy, evaluation of cancer risk factors, screening colonoscopy
Other · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
40 Years to 75 Years
Enrollment
8,108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2025
U.S. locations
4
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 29, 2026, 5:26 PM EDT
Terminated Not applicable Interventional Results available

A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver

NCT01098422
View directory record Official record
Conditions
Colorectal Neoplasms, Liver Neoplasms
Interventions
Yttrium-90 Radioactive Resin Microspheres
Device
Lead sponsor
Tony Reid, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 29, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer

NCT00100841
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
cetuximab, bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Oct 29, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Redes III Patient Navigator Qol Study

NCT02275754
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions
PN+LCNC, PN Only
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 29, 2026, 5:26 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

NCT04638751
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
Interventions
Immunotherapy, Chemotherapy, CRC surgical resection, Colonoscopy
Drug · Procedure
Lead sponsor
Persephone Biosciences
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
10
States / cities
Orange, California • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 29, 2026, 5:26 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

NCT03845166
View directory record Official record
Conditions
Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
Interventions
XL092, Atezolizumab, Avelumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
40
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 29, 2026, 5:26 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

ColoSense Post-Approval Study

NCT07069556
View directory record Official record
Conditions
Colorectal Cancer (Diagnosis)
Interventions
ColoSense
Device
Lead sponsor
Geneoscopy, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 29, 2026, 5:26 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Epigenetic Signature for CRC Early Detection

NCT07224854
View directory record Official record
Conditions
Colorectal Cancer (Diagnosis), Non-cancer Controls, DNA Methylation, Cell Free DNA, Early Detection of Cancer
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 29, 2026, 5:26 PM EDT
Terminated Not applicable Interventional

Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact

NCT04731441
View directory record Official record
Conditions
Colon Cancer, Ovarian Cancer, GI Cancer, Gynecologic Cancer
Interventions
Home-based Exercise Program Prior to CRS-HIPEC, Exercise Education
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 29, 2026, 5:26 PM EDT